MARKETS / NASDAQ / COSM
NASDAQ · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP

Cosmos Health Inc. COSM

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$65.3M
▲ 19.9% vs FY2024
EPS · FY25
$-0.63
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-89.1%
Net margin · FY25
-29.3%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 65.3M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.020.040.060.080.1-0.0201020132016201920222025
0.020.040.060.080.1-0.02016201920222025

The company lost 29 cents on every revenue dollar this year.

Per share
USD -0.63
Diluted EPS, FY2025
EPS
4000080000120000-0.63201020132016201920222025
4000080000120000-0.632016201920222025

The company pays no cash dividend.

Profitability
-89.1%
Return on equity, FY2025
ROE
80160240-89.1%201020132016201920222025
80160240-89.1%2016201920222025
Operating margin-25.6%
Net margin-29.3%
Return on assets-32.0%

Each USD of equity lost 89 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+3.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.0%
+3.3%
+61.7%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.020.04201020132016201920222025
0.010.042016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 65.5M
total assets, end of FY2025
Total assetsUSD 65.5M
EquityUSD 18.4M
CashUSD 715,674.00
Gross debtUSD 3.8M
Net debtUSD 3.1M
Current ratio1.00×

Net debt stands at 17% of equity.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
·
·
·
·
Income tax $B
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.63
−1.17
−2.15
−33.16
−23.74
0.06
−0.25
−0.68
−0.49
80741.00
−0.05
0.05
0.00
0.00
−0.01
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−89.1
−53.4
−49.2
−63.3
−7289.2
·
·
·
·
·
−316.5
223.1
·
·
·
·
Shares out B
0.04
0.02
0.02
0.01
0.00
0.01
0.01
0.01
0.01
0.01
0.13
0.13
0.13
0.10
0.02
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
53 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed